{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-249423","form_type":"8-K","ticker":"LITS","cik":"0001262104","company_name":"Lite Strategy, Inc.","filed_at":"2023-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.481204+00:00","generated_at":"2026-06-10T05:17:11.218043+00:00","sec_items":["1.01","3.03","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MEI Pharma adopts poison pill after Anson/Cable Car accumulate ~19.9% stake","bullets":["Rights plan triggers at 20% ownership; expires September 30, 2024.","Anson Advisors and Cable Car Capital hold ~19.9% of MEIP shares and sold put options for 1.5M additional shares.","Existing holders above 20% are grandfathered but cannot increase ownership without triggering plan.","Upon trigger, non-acquiring holders may purchase shares at twice the exercise price, causing dilution."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-249423","json":"https://secwatch.observer/filing/0001193125-23-249423.json","markdown":"https://secwatch.observer/filing/0001193125-23-249423.md","text":"https://secwatch.observer/filing/0001193125-23-249423.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523249423/0001193125-23-249423-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523249423/d559817d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T05:17:11.218043+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5796610d6690f71a7572df8d38b137cfa22e5d82","claim":"Lite Strategy, Inc.: Board approved Series A Certificate of Designation setting forth rights, powers, and preferences of Series A Preferred Shares (effective 2023-10-01).","evidence_excerpt":"on October 1, 2023, the Board approved the Series A Certificate of Designation. The Series A Certificate of Designation sets forth the rights, powers, and preferences of the Series A Preferred Shares.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523249423/0001193125-23-249423-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-10-01"}],"fact_type":"governance_change"},{"claim_id":"f654baa55b08eb0bed097fed2169eafddbdeaa97","claim":"Lite Strategy, Inc. entered into Rights Agreement with Computershare, Inc. (effective 2023-10-01).","evidence_excerpt":"On October 1, 2023, the Board of Directors (the “Board”) of MEI Pharma, Inc., a Delaware corporation (the “Company”), approved and adopted a Rights Agreement, dated as of October 1, 2023 (the “Rights Agreement”), by and between the Company and Computershare, Inc., as Rights Agent (the “Rights Agent”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523249423/0001193125-23-249423-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Computershare, Inc."},{"label":"Effective","value":"2023-10-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}